Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC By Ogkologos - June 2, 2026 67 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Nadofaragene Firadenovec April 24, 2026 Six Years of Adjuvant Imatinib Improves DFS Over Three Years Treatment... September 11, 2024 Health-Conscious Coffee Drinkers Are Ditching the Cream and Sugar in Favor... February 3, 2020 Daughter Surprises Terminally Ill Mom With Graduation Ceremony In Hospital Room. May 16, 2019 Load more HOT NEWS Sharing Energy Study Shows Thymic Health is Linked to Cancer Patients’ Response to... Jaw Problems Linked to Bone-Modifying Drugs Not as Rare as Once... Five Questions With…Francisco.
